Search Results

Findings from the Only Psoriasis Clinical Development Program for a Biologic Following Patients Continuously for Five Years Provide Insights on STELARA Long-Term Response and Safety Profile

Innovative Medicine

June 12, 2013

Five-Year SIMPONI Data Reported In Treatment Of Signs And Symptoms Of Moderately To Severely Active Rheumatoid Arthritis

Data from Three Pivotal Phase 3 Trials Presented at 2013 EULAR Annual Congres

Innovative Medicine

November 12, 2012

Phase 3 Data Show Intravenous Golimumab Inhibited Radiographic Progression In Patients With Active Rheumatoid Arthritis

Patients Receiving Intravenous Golimumab Showed Significant Improvements inSigns and Symptoms of Rheumatoid Arthritis through One Year According to New Study Findings

Innovative Medicine

October 22, 2012

New One-Year Phase 3 Study Results Show Anti-Tnf SIMPONI® Maintained Clinical Response In Treatment Of Moderately To Severely Active Ulcerative Colitis

Data Demonstrate Remission and Mucosal Healing with SIMPONI Maintenance Therapy

Innovative Medicine

March 29, 2013

U.S. FDA Approves INVOKANA™ (Canagliflozin) for the Treatment of Adults with Type 2 Diabetes

INVOKANA™ is the first in a new class of type 2 diabetes medications available in the United States In Phase 3 studies, INVOKANA™ improved blood glucose control and was associated with reductions in body weight and systolic blood pressure Janssen will partner with other Johnson & Johnson companies focused on diabetes to bring INVOKANA™ to healthcare professionals

Innovative Medicine

May 21, 2012

New Phase 3 Study Results Show Anti-TNF SIMPONI® Induced Clinical Response in Adults with Moderately To Severely Active Ulcerative Colitis

First Presentation of Phase 3 Data Shows Significant Improvements in Clinical Remission, Mucosal Healing and Quality of Life Measures after SIMPONI Induction Treatment

Search Results

No Results

Recently Viewed

Search Results